Pharmicell Co (XKRX:005690) Cash-to-Debt : 16.33 (As of Dec. 2024)

View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pharmicell Co's cash to debt ratio for the quarter that ended in Dec. 2024 was 16.33.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pharmicell Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Pharmicell Co's Cash-to-Debt or its related term are showing as below:

XKRX:005690' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.54 Med: 6.49 Max: No Debt
Current: 16.33

During the past 13 years, Pharmicell Co's highest Cash to Debt Ratio was No Debt. The lowest was 1.54. And the median was 6.49.

XKRX:005690's Cash-to-Debt is ranked better than
60.19% of 1482 companies
in the Biotechnology industry
Industry Median: 7.595 vs XKRX:005690: 16.33

Pharmicell Co Cash-to-Debt Historical Data

The historical data trend for Pharmicell Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pharmicell Co Cash-to-Debt Chart

Pharmicell Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

8.47

2.10

1.54

4.63

16.33

Pharmicell Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															4.63	3.40	7.79	16.41	16.33

Competitive Comparison of Pharmicell Co's Cash-to-Debt

For the Biotechnology subindustry, Pharmicell Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmicell Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmicell Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pharmicell Co's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Pharmicell Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pharmicell Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11200.837	/	(258.699	+	427.303)
	=	16.33

Pharmicell Co's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11200.837	/	(258.699	+	427.303)
	=	16.33

Pharmicell Co (XKRX:005690) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pharmicell Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmicell Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010

Website

http://www.pharmicell.com

Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co Headlines

No Headlines